Xiyouji Qingzhi Capsule recall
XIYOUJI QINGZHI CAPSULE, 300mg, 20 count box
Why was Xiyouji Qingzhi Capsule recalled?
Marketed without an Approved NDA/ANDA: Products found to contain undeclared sibutramine. Sibutramine was removed from the U.S. market for safety reasons, making these products unapproved new drugs.
What should I do if I have this product?
Review the official FDA enforcement record for current instructions.
What to do with a recalled product: refunds, receipts, safe disposal and how to report a problem.
Is my product affected?
Compare the item in your hand with every identifier below from the official FDA record. Only products that match the listed product and lot, UPC or model codes are part of this recall.
Which lot codes, UPCs or models are affected?
All Lots
- Product
- XIYOUJI QINGZHI CAPSULE, 300mg, 20 count box
- Recalling firm
- Dolphin Intertrade Corporation
- Quantity
- 8 bottles
- Distribution
- Nationwide
- Recall date
- April 30, 2014
- Classification
- Class I
- Status
- Terminated
- Agency
- FDA (drug)